Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Marref, Imène; Romain, Gaëlle; Jooste, Valerie; Vendrely, Véronique; Lopez, Anthony; Faivre, Jean; Gerard, Jean Pierre; Bouvier, Anne-Marie; Lepage, Côme
• Is Part Of: Digestive and liver disease. Volume 53:Issue 11(2021)
• Page Start: 1492
• Page End: 1498
• Publication Date: 2021-11
• Subjects: Anal cancer -- Management -- Recurrence -- Net-survival -- Cancer registry; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2021.05.028
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Little is known about the management of squamous cell carcinoma of the anal canal and its recurrence at a population level. The aim of this study was to draw a picture of management, recurrence and survival in squamous cell carcinoma of the anal canal. Material and methods: The 5-year probability of recurrences was estimated using the cumulative incidence function to consider competing risks of death. Net survival was estimated and a multivariate survival analysis was performed. The study was conducted using data of the Burgundy Digestive Cancer Registry. Overall, 273 squamous cell carcinomas of the anal canal registered between 1998 and 2014 were considered. Results: Overall, 80% of patients were treated with curative intent. Of these, 61% received chemoradiotherapy, 35% received radiotherapy and 4% received abdominoperineal resection alone. After these treatments, for cure the 5-year cumulative recurrence rate was 27% overall; it was 20% after chemoradiotherapy and 38% after radiotherapy. Five-year net survival was 71% overall; it was 81% after chemoradiotherapy and 55% after radiotherapy. Conclusions and relevance: Chemoradiotherapy was highly effective in routine practice. We confirm that it is difficult to distinguish between persistent active disease and local inflammation due to radiotherapy. Squamous cell carcinoma of the anal canal recurrences remains a substantial problem, highlighting the interest of prolonged surveillance. Aggressive management of recurrences may be beneficial.